Zobrazeno 1 - 10
of 623
pro vyhledávání: '"JAE CHEOL LEE"'
Autor:
Kyu Jin Song, Seunghyuk Choi, Kwoneel Kim, Hee Sang Hwang, Eunhyong Chang, Ji Soo Park, Seok Bo Shim, Seunghwan Choi, Yong Jin Heo, Woo Ju An, Dae Yeol Yang, Kyung-Cho Cho, Wonjun Ji, Chang-Min Choi, Jae Cheol Lee, Hyeong-ryul Kim, Jiyoung Yoo, Hee-Sung Ahn, Gang-Hee Lee, Chanwoong Hwa, Seoyeon Kim, Kyunggon Kim, Min-Sik Kim, Eunok Paek, Seungjin Na, Se Jin Jang, Joon-Yong An, Kwang Pyo Kim
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-25 (2024)
Abstract Non-small cell lung cancer (NSCLC) is histologically classified into lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LSCC). However, some tumors are histologically ambiguous and other pathophysiological features or microenvironm
Externí odkaz:
https://doaj.org/article/eab1236f06004ebd9eac6feafccb85e5
Autor:
Soo Jin Han, Hyeon Hwa Kim, Dong-gon Hyun, Wonjun Ji, Chang-Min Choi, Jae Cheol Lee, Ho Cheol Kim
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Lung cancer (LC) is an important comorbidity of interstitial lung disease (ILD) and has a poor prognosis. The clinical characteristics and outcome of each ILD subtype in LC patients have not been sufficiently investigated. Therefo
Externí odkaz:
https://doaj.org/article/1e55b86fda2241a590c1143eb336ffee
Publikováno v:
Thoracic Cancer, Vol 14, Iss 33, Pp 3323-3330 (2023)
Abstract Background Although acute exacerbation (AE) after treatment for lung cancer (LC) is a poor prognostic factor in patients with interstitial lung disease associated with lung cancer (ILD‐LC), the risk of AE according to cancer treatment type
Externí odkaz:
https://doaj.org/article/df8521a0fb18414eb22e9d35343cce0e
Publikováno v:
Thoracic Cancer, Vol 14, Iss 31, Pp 3080-3088 (2023)
Abstract Background As the outcome of immunotherapy can be improved when concurrently or sequentially combined with cytotoxic chemotherapy or radiotherapy, we investigated the efficacy of immunotherapy maintenance following platinum‐based chemother
Externí odkaz:
https://doaj.org/article/3b9c6bcbd1a04501b7e94861cd585faf
Autor:
Dong Ha Kim, Hyojeong Park, Yun Jung Choi, Kyungtaek Im, Chae Won Lee, Da-Som Kim, Chan-Gi Pack, Hyun-Yi Kim, Chang-Min Choi, Jae Cheol Lee, Wonjun Ji, Jin Kyung Rho
Publikováno v:
Biomarker Research, Vol 11, Iss 1, Pp 1-14 (2023)
Abstract Background Small cell lung cancer (SCLC) has an exceptionally poor prognosis; as most of the cases are initially diagnosed as extensive disease with hematogenous metastasis. Therefore, the early diagnosis of SCLC is very important and may im
Externí odkaz:
https://doaj.org/article/004a40481b604424bf05974497000327
Autor:
Bora Lee, Wonjun Ji, Jae Cheol Lee, Si Yeol Song, Young Seob Shin, Young Hyun Cho, Ji Eun Park, Hyungjun Park, Chang‐Min Choi
Publikováno v:
Thoracic Cancer, Vol 14, Iss 22, Pp 2233-2237 (2023)
Abstract Introduction Non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation has a higher incidence of brain metastases than wild‐type EGFR mutations. Osimertinib, a third‐generation EGFR tyrosine kinase inhibi
Externí odkaz:
https://doaj.org/article/a03344443e1d4db4b93f7a21a61f2f2e
Autor:
Yong Man Kim, Gun Woo Son, Wonjun Ji, Mi Young Choi, Jae Seob Jung, Myeong Geun Choi, Jin Kyung Rho, Byeong Gon Yoon, Jong-Min Jo, Dae-Hyun Ko, Jae Cheol Lee, Chang-Min Choi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Choosing treatments for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients with osimertinib resistance is challenging. We evaluated the safety and efficacy of SNK01 (autologous natural killer (NK) c
Externí odkaz:
https://doaj.org/article/bbc55702f6b84ce89b98c71d1bfb905e
Autor:
Min-Hyung Kim, Sojung Park, Yu Rang Park, Wonjun Ji, Seul-Gi Kim, Minji Choo, Seung-Sik Hwang, Jae Cheol Lee, Hyeong Ryul Kim, Chang-Min Choi
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background To validate a stratification method using an inverse of treatment decision rules that can classify non-small cell lung cancer (NSCLC) patients in real-world treatment records. Methods (1) To validate the index classifier against t
Externí odkaz:
https://doaj.org/article/8731e3e539d64b1693b32a8d2af12c0f
Autor:
Da Som Jeon, Jin Woo Kim, Seul Gi Kim, Hyeong Ryul Kim, Si Yeol Song, Jae Cheol Lee, Wonjun Ji, Chang‐Min Choi, Ho Cheol Kim, Korean Association for Lung Cancer, South Korea Central Cancer Registry
Publikováno v:
Thoracic Cancer, Vol 13, Iss 18, Pp 2584-2591 (2022)
Abstract Purpose This study aimed to investigate the differences in characteristics, clinical stages, treatment modalities, and survival outcomes in patients with non‐small‐cell lung cancer (NSCLC) based on sex differences using Korean nationwide
Externí odkaz:
https://doaj.org/article/75c190ca8a7049dabaa3780fac9ff56c
Publikováno v:
Thoracic Cancer, Vol 13, Iss 14, Pp 2050-2056 (2022)
Abstract Background A previous trial showed that autologous ex‐vivo expanded NK cell (SNK01) treatment combined with pembrolizumab showed better efficacy than pembrolizumab monotherapy in advanced non‐small cell lung cancer (NSCLC). This study wa
Externí odkaz:
https://doaj.org/article/6e9497873ed4426aac22d60ad24694a2